These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 1678860)

  • 1. Phenylalkylamine stimulants, hallucinogens, and designer drugs.
    Glennon RA
    NIDA Res Monogr; 1990; 105():154-60. PubMed ID: 1678860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative stimulus properties of hallucinogens and related designer drugs.
    Glennon RA
    NIDA Res Monogr; 1991; (116):25-44. PubMed ID: 1369672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships.
    Glennon RA
    NIDA Res Monogr; 1989; 94():43-67. PubMed ID: 2575229
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs.
    Gold LH; Geyer MA; Koob GF
    NIDA Res Monogr; 1989; 94():101-26. PubMed ID: 2514360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical toxicology of newer recreational drugs.
    Hill SL; Thomas SH
    Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline.
    Glennon RA; Young R; Rangisetty JB
    Pharmacol Biochem Behav; 2002 May; 72(1-2):379-87. PubMed ID: 11900809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex.
    Berridge CW; Stalnaker TA
    Synapse; 2002 Dec; 46(3):140-9. PubMed ID: 12325041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.
    Oberlender R; Nichols DE
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1098-106. PubMed ID: 1979813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA).
    Broadbent J; Appel JB; Michael EK; Ricker JH
    Behav Pharmacol; 1992 Oct; 3(5):443-454. PubMed ID: 11224147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of hallucinogenic drugs on the activity of serotonin-containing neurons in the nucleus centralis superior and nucleus raphe pallidus in freely moving cats.
    Trulson ME; Preussler DW; Trulson VM
    J Pharmacol Exp Ther; 1984 Jan; 228(1):94-102. PubMed ID: 6694110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems.
    Battaglia G; De Souza EB
    NIDA Res Monogr; 1989; 94():240-58. PubMed ID: 2514364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
    Rothman RB; Baumann MH; Dersch CM; Romero DV; Rice KC; Carroll FI; Partilla JS
    Synapse; 2001 Jan; 39(1):32-41. PubMed ID: 11071707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual differences in responses to ethanol and d-amphetamine: a within-subject study.
    Holdstock L; de Wit H
    Alcohol Clin Exp Res; 2001 Apr; 25(4):540-8. PubMed ID: 11329494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Legal highs" - new players in the old drama.
    Zawilska JB
    Curr Drug Abuse Rev; 2011 Jun; 4(2):122-30. PubMed ID: 21711229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo.
    Johanson CE; Kilbey M; Gatchalian K; Tancer M
    Drug Alcohol Depend; 2006 Jan; 81(1):27-36. PubMed ID: 15975736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2C or not 2C: phenethylamine designer drug review.
    Dean BV; Stellpflug SJ; Burnett AM; Engebretsen KM
    J Med Toxicol; 2013 Jun; 9(2):172-8. PubMed ID: 23494844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arylalkylamine drugs of abuse: an overview of drug discrimination studies.
    Glennon RA
    Pharmacol Biochem Behav; 1999 Oct; 64(2):251-6. PubMed ID: 10515299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Entactogen and designer drugs].
    Naito H
    Chudoku Kenkyu; 2010 Mar; 23(1):3-15. PubMed ID: 20380315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.